A few days ago, Merck lent evidence to that conjecture with a readout from the phase 3 KEYLYNK-001 trial in first-line ovarian cancer. There, Keytruda’s addition to Lynparza maintenance—plus ...

Read also: Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival in Patients With Advanced Epithelial Ovarian Cancer: Merck ...

The phase 3 KEYLYNK-001 trial has been evaluating Merck’s anti-PD-1 therapy Keytruda in combination with chemotherapy followed by maintenance with the company’s AstraZeneca-partnered PARP inhibitor ...

Merck is conducting the Phase 3 Keylynk-001 trial investigating the efficacy of its leading oncology drug, Keytruda (pembrolizumab, anti-PD-L1) plus chemotherapy followed by maintenance treatment ...

New Amsterdam Pharma said that its CETP inhibitor succeeded in its third Phase 3 trial. Merck said its Phase 3 KEYLYNK-001 trial met the primary endpoint of progression-free survival in patients with ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the Phase 3 KEYLYNK-001 trial evaluating KEYTRUDA (pembrolizumab) plus chemotherapy followed by maintenance with ...

Recently, Merck announced topline data from the Phase 3 KEYLYNK-001 trial of Keytruda (pembrolizumab) plus chemotherapy followed by maintenance with Lynparza, with or without bevacizumab ...

Merck, known as MSD outside of the United States and Canada, announced that the phase 3 KEYLYNK-001 trial evaluating Keytruda (pembrolizumab) plus chemotherapy followed by maintenance with Lynparza ...

Merck MRK announced that its phase III KEYLYNK-001 study, evaluating its blockbuster anti-PD-1 therapy Keytruda regimen in advanced epithelial ovarian cancer met the primary endpoint of ...